Janux reports positive interim Phase 1a data for PSMA-TRACTr and EGFR-TRACTr; cash at $338.2M

Janux Therapeutics, Inc.

At JANX007 starting dose ≥0.2 mg, 6/6 (100%) achieved PSA30 and 5/6 (83%) PSA50; one PSA90 observed.
CRS for JANX007 only Grade 1/2 and transient; doses up to 3 mg with no MTD reached.
JANX008: One NSCLC subject with confirmed PR (100% lung target reduction, liver mets eliminated); no CRS or TRAEs.
11 heavily pre-treated subjects enrolled across four tumor types in JANX008; no SAEs or DLTs.
Preliminary cash, equivalents, and short-term investments ~$338.2M as of Jan 31, 2024 (incl. $0.8M restricted).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.